Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: DETROL LA

« Back to Dashboard
Detrol La is a drug marketed by Pharmacia And Upjohn and is included in one NDA. It is available from seven suppliers. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in DETROL LA is tolterodine tartrate. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the tolterodine tartrate profile page.

Summary for Tradename: DETROL LA

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list30

Pharmacology for Tradename: DETROL LA

Clinical Trials for: DETROL LA

A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Completed Condition: Overactive Bladder (OAB)

Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Status: Completed Condition: Benign Prostatic Hyperplasia (BPH)

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Status: Completed Condition: Healthy

Detrol LA In Men With Overactive Bladder.
Status: Completed Condition: Overactive Bladder (OAB)

Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Status: Completed Condition: Overactive Bladder

Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
Status: Completed Condition: Overactive Bladder

Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine
Status: Completed Condition: Pharmacokinetics of Mirabegron and Tolterodine; Healthy

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
Status: Terminated Condition: Urinary Incontinence

Effects Of Detrol LA On Memory And Cognition In Elderly Population
Status: Completed Condition: Memory; Cognition

Detrol LA vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms
Status: Completed Condition: Overactive Bladder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-001Dec 22, 2000RXNo6,911,217*PED<disabled>Y<disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-002Dec 22, 2000RXYes6,911,217*PED<disabled>Y<disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-001Dec 22, 2000RXNo6,770,295*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DETROL LA

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-001Dec 22, 20005,382,600*PED<disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-002Dec 22, 20005,559,269*PED<disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-001Dec 22, 20005,559,269*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DETROL LA

Drugname Dosage Strength RLD Submissiondate
tolterodine tartrateExtended-release Capsules2 mg and 4 mgDetrol LA7/30/2007
« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc